US › Healthcare

Aurinia Pharmaceuticals Inc (AUPH)

US · Healthcare · Biotechnology

$14.93+2.47%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$77.7M
Revenue YoY
+24.4%
Net profit
$34.4M
Profit YoY
+47.2%
EPS
$0.25
EPS estimate
$0.16
Net margin
44.2%

EPS came in at 0.25 against a street estimate of 0.16 — a beat of 56.2%.

Key statistics

Market cap
$1.87B
P/E
6.7
Forward P/E
17.0
P/B
3.37
Book value
$4.34
EPS (TTM)
$2.16
52-week high
$19.25
52-week low
$10.34
50-day MA
$15.93
200-day MA
$15.15
Beta
1.40

Analyst view

Analysts rate Aurinia Pharmaceuticals Inc a buy (5 buy, 1 hold, 0 sell out of 6) with an average price target of $17.00.

Shareholding

Insiders
7.53%
Institutions
60.74%

Largest institutional holders

FundStake
TANG CAPITAL MANAGEMENT LLC9.51%
BlackRock Inc6.10%
NEA Management Company, LLC3.09%
Two Sigma Investments LLC2.67%
Arrowstreet Capital Limited Partnership2.55%
State Street Corp1.97%
Morgan Stanley - Brokerage Accounts1.74%
Marshall Wace Asset Management Ltd1.46%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Aurinia Pharmaceuticals Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.